Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (323)	12/10/1998 6:23:00 PM
From: tom pope	Read Replies (1) \| Respond to of 1386

Would it be possible to direct us to a URL listing the participants? Many TIA

To: Dr. John M. de Castro who wrote (323)	12/10/1998 7:37:00 PM
From: yosi s	Respond to of 1386

I guess management like where we are. Or they do not like it and cannot help it but find themselves here. Either way. They got to get LE tobra rolling. NDA in Europe Go forward with HU 211. or get new management........

To: Dr. John M. de Castro who wrote (323)	12/10/1998 8:06:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1386

In the current biotech climate, dog-and-pony shows do not do much for companies. Last year, more companies went down after their presentation at H&Q than went up (40 to 38, per BioCentury). PARS prospects will depend on actual events--e.g. HU211 partnering--and perhaps strategic meetings with institutional investors 1 on 1--not 15 minutes at a cattle show. NeuroInvestment (www.neuroinv.com)